Results 251 to 260 of about 2,494,673 (310)

Targeting solid tumors with TCR-T cells: mechanisms, progress, and challenges. [PDF]

Front Oncol
Hu W, Zhang Z, Pan M, Wang W, Wang Z.
europepmc   +1 more source

Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors. [PDF]

Front Immunol
Lim JU, Tao D, Selvadurai PN, Dumbrava EE, Naing A, Champiat S, Mirallas O, Kang L, Le H, Tsimberidou AM, Ahnert JR, Piha-Paul SA, Fu S, Yap TA, Tang TY, Meric-Bernstam F, Sheshadri A, Hong DS.   +17 more
europepmc   +1 more source

Irinotecan plus temozolomide for pediatric relapsed or refractory solid tumors: a retrospective cohort study. [PDF]

Transl Pediatr
Fang J, Zhang Y, Liu Q, Dong Z, Gong H, Zhou W, Wang Y, Liu H.   +7 more
europepmc   +1 more source

Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions. [PDF]

Cell Rep Med
Manzar GS, Hasan MF, Moore M, Tiberti S, Osorio NP, Basar R, Daher M.   +6 more
europepmc   +1 more source

The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications. [PDF]

Int J Mol Sci
Boutier H, Feldmann A, Bachmann M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

BAP1 In Solid Tumors

Future Oncology, 2019
One of the most attractive cancer-related genes under investigation is BAP1. Reasons of this growing interest are related to the wide spectrum of pathways directly or indirectly modulated by this gene and shared by several solid tumors. Programmed cell-death, cell metabolisms, immune cells development, ferroptosis and defects in DNA damage response are
Di Nunno V., Frega G., Santoni M., Gatto L., Fiorentino M., Montironi R., Battelli N., Brandi G., Massari F.   +8 more
openaire   +3 more sources

Sunitinib in solid tumors

Expert Opinion on Investigational Drugs, 2009
Until recently, few treatments were available for renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). Several targeted agents inhibiting key pathogenetic pathways have since been developed for RCC (sunitinib, sorafenib, bevacizumab, temsirolimus, everolimus) and GIST (imatinib, sunitinib).
Hui K, Gan, Bostjan, Seruga, Jennifer J, Knox   +2 more
openaire   +2 more sources